Agenda IB
Elizabeth Bilsland
The current COVID-19 pandemic highlighted the vulnerability of our society to infections diseases. Whilst the current media focus is centered on SARS-CoV2, we must be prepared for the threat posed by drug-resistant parasites, fungi, and bacteria. The Synthetic Biology Laboratory (LaBS) was established in 2016 and is based on synthetic biology as a tool for drug discovery, using yeast and bacteria as hosts for heterologous expression and a platform for genome-wide screens. We have 3 well-established lines of investigation, which can further be improved and rapidly yield results. We are also introducing a novel highly ambitious line of research, taking advantage of our strong international collaboration network, for the development of novel antimicrobials inspired by secondary metabolites from native actinomycetes, filamentous fungi, or plant species.
Fernando Roberto Martins
Ecology of natural plant populations and communities, especially in the Caatinga, Cerrado, and Atlantic Forest;
Paulo Henrique Ferreira Caria
Morphofunctional behavior of the musculoskeletal system. Currently is collaborator in the OncoTherad nanopharmaceutical development laboratory with application in the treatment of oral cancer.